

Medical Products AgencyCERTIFICATE NUMBER : **5.9.1-2021-033386****CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER**^{1, 2}**Part 1**

Issued following an inspection in accordance with :
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Sweden confirms the following:

The manufacturer : **Pfizer Health AB**

Site address : **Mariefredsvägen 37, Strängnäs, 645 41, Sweden**

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. **5.9.1-2020-072018** in accordance with Art. 40 of Directive 2001/83/EC .

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC .

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2017-10-13** , it is considered that it complies with :

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC³
- The principles of GMP for active substances³ referred to in Article 47 of Directive 2001/83/EC .

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.



Part 2

1 MANUFACTURING OPERATIONS	
1.3	Biological medicinal products (list of product types)
	<i>1.3.1 Biological medicinal products (list of product types)</i> 1.3.1.5 Biotechnology products 1.3.1.8 Other: Cellbank(en)
1.6	Quality control testing
	1.6.2 Microbiological: non-sterility 1.6.3 Chemical/Physical 1.6.4 Biological

Manufacture of active substance. Names of substances subject to inspection :

ANAKINRA(en)


DALTEPARIN SODIUM(en)

SOMATROPIN(en)

B2036 INTERMEDIATE(en)

TRUMENBA(en)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES	
Active Substance :ANAKINRA	
3.3	Manufacturing of Active Substance using Biological Processes
	3.3.1 Fermentation
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing 3.6.4 Biological Testing
Active Substance :DALTEPARIN SODIUM	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.2 Manufacture of crude active substance
3.5	General Finishing Steps
	3.5.1 Physical processing steps: Milling and drying 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing



	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
Active Substance :SOMATROPIN	
3.3	Manufacturing of Active Substance using Biological Processes
	3.3.1 Fermentation
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing 3.6.4 Biological Testing
Active Substance :B2036 INTERMEDIATE	
3.3	Manufacturing of Active Substance using Biological Processes
	3.3.1 Fermentation
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing 3.6.4 Biological Testing
Active Substance :TRUMENBA	
3.3	Manufacturing of Active Substance using Biological Processes
	3.3.1 Fermentation
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing 3.6.4 Biological Testing



Clarifying remarks (for public users)

1.3.1.5 Manufacturing of biotech drug substances and intermediates based on recombinant bacterial products or polysaccharide. (Tillverkning av bioteknologiska aktiva substanser och intermediat baserade på rekombinanta bakteriella produkter eller polysackarider.) 1.3.1.8 Manufacturing and storage of cellbank. (Tillverkning och förvaring av cellbank.)

2021-06-09

Name and signature of the authorised person of the
Competent Authority of Sweden



Mr. Bengt Berglund
Medical Products Agency
Tel: +46 18 174600
Fax: +46 18 548566